Monoclonal antiidiotypic antibodies neutralize cytotoxic effects of anti-alpha Gal antibodies

被引:25
作者
Koren, E
Milotic, F
Neethling, FA
Koscec, M
Fei, D
Kobayashi, T
Taniguchi, S
Cooper, DKC
机构
[1] OKLAHOMA MED RES FDN,OKLAHOMA CITY,OK 73104
[2] BAPTIST MED CTR,OKLAHOMA TRANSPLANTAT INST,OKLAHOMA CITY,OK 73112
关键词
D O I
10.1097/00007890-199609270-00023
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The aims of this study were to produce and characterize mouse monoclonal antiidiotypic antibodies (AIAs) that specifically bind human antipig (anti-alpha Gal) antibodies and to select those AIAs that neutralize the cytotoxicity of human or baboon serum to pig (PK15) cells. Mice were immunized with human antipig antibodies, and hybridomas were produced using conventional techniques. From a total of 480 clones, 11 produced AIAs that bound with high affinity to human anti-alpha Gal IgG and F(ab')(2) fragments, and individually reduced serum cytotoxicity to pig cells by 40-90%. Seven of the AIAs also bound to human peripheral B lymphocytes (that express the same idiotypes as the antibodies they produce), Several combinations of two or three AIAs provided 100% protection of PK15 cells. Selected AIAs injected intravenously into baboons reduced the cytotoxicity of subsequently drawn sera by 50-80% for >48hr. The cytotoxicity studies also indicated that there are at least two dominant idiotypes expressed in the human anti-alpha Gal population, We conclude that AIAs against anti-alpha Gal antibodies could be successfully used in (1) preoperative characterization of a recipient's anti-alpha Gal profile, (2) prevention of hyperacute rejection of a pig organ, and (3) specific immunosuppression through elimination of anti-alpha Gal-producing B lymphocytes.
引用
收藏
页码:837 / 843
页数:7
相关论文
共 31 条
  • [1] ENGINEERING ANTIBODIES FOR THERAPY
    ADAIR, JR
    [J]. IMMUNOLOGICAL REVIEWS, 1992, 130 : 5 - 40
  • [2] AMLOT PL, 1993, BLOOD, V82, P2624
  • [3] BANNETT AD, 1987, TRANSPLANT P, V19, P4543
  • [4] CALNE RY, 1970, TRANSPL P, V2, P550
  • [5] COOKE A, 1993, IMMUNOLOGY, P94
  • [6] Cooper D K, 1993, Transpl Immunol, V1, P198, DOI 10.1016/0966-3274(93)90047-C
  • [7] COOPER DKC, 1992, TRANSPLANT P, V24, P566
  • [8] GENETICALLY-ENGINEERED PIGS
    COOPER, DKC
    KOREN, E
    ORIOL, R
    [J]. LANCET, 1993, 342 (8872) : 682 - 683
  • [9] SPECIFIC INTRAVENOUS CARBOHYDRATE THERAPY - A NEW CONCEPT IN INHIBITING ANTIBODY-MEDIATED REJECTION EXPERIENCE WITH ABO-INCOMPATIBLE CARDIAC ALLOGRAFTING IN THE BABOON
    COOPER, DKC
    YE, Y
    NIEKRASZ, M
    KEHOE, M
    MARTIN, M
    NEETHLING, FA
    KOSANKE, S
    DEBAULT, LE
    WORSLEY, G
    ZUHDI, N
    ORIOL, R
    ROMANO, E
    [J]. TRANSPLANTATION, 1993, 56 (04) : 769 - 777
  • [10] OLIGOSACCHARIDES AND DISCORDANT XENOTRANSPLANTATION
    COOPER, DKC
    KOREN, E
    ORIOL, R
    [J]. IMMUNOLOGICAL REVIEWS, 1994, 141 : 31 - 58